Skip to main navigation
Caribou Biosciences, Inc. Logo

Quarterly results

Show all

2024

Q3

  • Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
  • Form 10-Q

Q2

  • Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
  • Form 10-Q

Q1

  • Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
  • Form 10-Q

2023

Q4

  • Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
  • Form 10-K

Q3

  • Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
  • Form 10-Q

Q2

  • Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
  • Form 10-Q

Q1

  • Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
  • Form 10-Q

2022

Q4

  • Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
  • Form 10-K

Q3

  • Earnings release
  • Form 10-Q

Q2

  • Earnings release
  • Form 10-Q

Q1

  • Earnings release
  • Form 10-Q

2021

Q4

  • Earnings release
  • Form 10-K

Q3

  • Earnings release
  • Form 10-Q

Q2

  • Earnings release
  • Form 10-Q

Print page

Email alerts

RSS feeds

Investor contact

  • News & events
    • Press releases
    • Events
    • Presentations
  • Stock information
    • Stock quote & chart
    • Analyst coverage
  • Corporate governance
    • Documents & charters
    • Leadership
    • Board of Directors
    • Committee composition
    • Board diversity matrix
  • Financials & filings
    • SEC filings
    • Annual reports
    • Quarterly results
  • IR resources
    • FAQs
    • Email alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • CAR-NK cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical trials
    • Careers
      • Job opportunities
      • Values
      • DE&I
      • Benefits
    • Investors
      • News & events
        • Press releases
        • Events
        • Presentations
      • Stock information
        • Stock quote & chart
        • Analyst coverage
      • Corporate governance
        • Documents & charters
        • Leadership
        • Board of Directors
        • Committee composition
        • Board diversity matrix
      • Financials & filings
        • SEC filings
        • Annual reports
        • Quarterly results
      • IR resources
        • FAQs
        • Email alerts
        • Contact IR
    • Contact
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • CAR-NK cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical trials
    • Careers
      • Job opportunities
      • Values
      • DE&I
      • Benefits
    • Investors
      • News & events
        • Press releases
        • Events
        • Presentations
      • Stock information
        • Stock quote & chart
        • Analyst coverage
      • Corporate governance
        • Documents & charters
        • Leadership
        • Board of Directors
        • Committee composition
        • Board diversity matrix
      • Financials & filings
        • SEC filings
        • Annual reports
        • Quarterly results
      • IR resources
        • FAQs
        • Email alerts
        • Contact IR
    • Contact

    Caribou Biosciences, Inc. Logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030

    © 2024 Caribou Biosciences, Inc. All rights reserved.
    • Privacy policy
    • Terms of use
    • Twitter
    • linkedin
    Website Design: Hane Chow, Inc .